Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Details)

v3.22.4
Stock-Based Compensation (Details) - USD ($)
3 Months Ended 9 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Stock-Based Compensation        
Stock-based compensation expense $ 31,000 $ 200,000 $ 100,000 $ 300,000
Vesting period     1 year 5 years
Weighted-average grant date fair value     $ 0.30 $ 2.05
Risk free interest rate     3.95% 1.34%
Expected term     7 years 7 years
Expected volatility     197.00% 171.00%
Forfeiture rate     0.00% 0.00%
Employees of Bionik Inc        
Stock-Based Compensation        
Share options granted     244,000 273,500
Performance Based Units (PSUs)        
Stock-Based Compensation        
Unrecognized compensation expense $ 200,000   $ 200,000  
Expects to recognize over weighted-average period     2 years